Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272870 | 0.82 | KDM4E (0.49) | SIGMAR1ACP1 | |
| SCHEMBL2793769 | 0.79 | IKBKB (0.40) | PIM1PIM3BRSK1AURKBMKNK2 | |
| SCHEMBL2790826 | 0.75 | HCAR3 (0.37) | MKNK2CCNA2CDK2KCNH2 | |
| SCHEMBL2791507 | 0.75 | HCAR3 (0.44) | — | |
| SCHEMBL4072626 | 0.75 | HRH3 (0.47) | PIM1SIGMAR1TMEM97TNIKCSNK2A1 | |
| SCHEMBL1126248 | 0.74 | ALDH1A1 (0.38) | — | |
| SCHEMBL2792642 | 0.74 | CD38 (0.41) | KCNH2 | |
| SCHEMBL2791917 | 0.73 | VCP (0.38) | PIM1KCNH2 | |
| SCHEMBL2790959 | 0.73 | ALDH1A1 (0.40) | PIM1 | |
| SCHEMBL30969255 | 0.71 | NNMT (0.50) | PIM1FLT3PIM3BRSK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686130-B1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | PFIZER PROD INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-7192963-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1686130-A1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | Pfizer Products Incorporated (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1294724-B1 | PYRROLO¬2,3-D|PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6962993-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2005-09-08 | — | — | US | disclosed |
| US-6696567-B2 | INHIBITION OF PROTEIN KINASES OR JANUS KINASE 3; TREATING OR PREVENTING ORGAN TRANSPLANT REJECTION, XENO TRANSPLATION, LUPUS, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, TYPE I DIABETES OR VARIOUS DISEASE COMPLICATIONS | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | PIM1 91/4885FLT3 134/4885PIM3 97/4885 |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | CDK2, CDK3, JAK3 | PIM1 136/4885FLT3 50/4885PIM3 66/4885 |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | PIM1 91/4885FLT3 134/4885PIM3 97/4885 |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | CDK2, CDK3, JAK3 | PIM1 136/4885FLT3 50/4885PIM3 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.